Published in final edited form as:

J Pharm Pharmacol (Los Angel). ; 1(1): 001–. doi:10.13188/2327-204X.1000001.

The Role of Glycogen Synthase Kinase 3 Beta in Neuroinflammation and Pain

Dylan Warren Maixner and Han-Rong Weng*

Department of Pharmaceutical and Biomedical Sciences, The University of Georgia College of Pharmacy, Athens, Georgia, 30606, USA

Abstract

Neuroinflammation is a crucial mechanism related to many neurological diseases. Extensive studies in recent years have indicated that dysregulation of Glycogen Synthase Kinase 3 Beta (GSK3 β) contributes to the development and progression of these disorders through regulating the neuroinflammation processes. Inhibitors of GSK3 β have been shown to be beneficial in many neuroinflammatory disease models including Alzheimer's disease, multiple sclerosis and AIDS dem entia complex. Glial activation and elevated pro-inflammation cytokines (signs of neuroinflammation) in the spinal cord have been widely recognized as a pivotal mechanism underlying the development and maintenance of many types of pathological pain. The role of GSK3 β in the pathogenesis of pain has recently emerged. In this review, we will first review the GSK3 β structure, regulation, and mechanisms by which GSK3 β regulates inflammation. We will then describe neuroinflammation in general and in specific types of neurological diseases and the potential beneficial effects induced by inhibiting GSK3 β . Finally, we will provide new evidence linking aberrant levels of GSK3 β in the development of pathological pain.

Introduction

Glycogen synthase kinase 3 (GSK3) is a serine/threonine protein kinase, which is part of the mitogen activated protein (MAP) kinase family and is pivotal in many signaling cascades [1]. GSK3 is important in metabolism and signaling in development. The role of GSK3 β in mediating peripheral and central nervous system inflammation in a multitude of neurological disorders has been extensively studied [2-6]. Studies of the role of GSK3 β in pathological pain have recently just started [5,7]. In the brain, GSK3 β is localized primarily to neurons [8], but has also been shown to be in glial cells [9].

Inflammation of the brain has become recognized as a common feature shared by many neurological disorders like Alzheimer's disease [10-12], schizophrenia [13,14], multiple sclerosis [15,16], and HIV induced dementia [17,18]. Aberrant levels or activities of GSK3 play a critical role in the development of these diseases and pharmacological inhibition of GSK3 β ameliorates these diseases [19-23]. Inflammation is also a critical component

contributing to the development and maintenance of pathological pain induced by peripheral tissue or nerve injury. Accumulation of inflammatory cells including macrophages, neutrophils at the peripheral injury site and the dorsal root ganglion, proliferation and activation of microglia and astrocytes in the spinal dorsal horn, as well as the release of pro-inflammatory cytokines and other pro-inflammatory mediators in the injury site, the dorsal root ganglion and the spinal dorsal horn have all been shown to contribute to the development and maintenance of pathological pain [24-27]. Similarly, pharmacological inhibition of GSK3 β has been recently shown to attenuate pathological pain induced by nerve injury or formalin injection [5,7].

In this review, we will first briefly discuss the history, structure, regulation, and pharmacology of GSK3 β . We will then provide an overview of neurological diseases including pathological pain where neuroinflammation plays a crucial role and how GSK3 β may play a role in the progression of these diseases.

Brief History, Functional Properties, and Structural Insights of GSK

Glycogen Synthase Kinase 3 (GSK3) was first purified from rabbit skeletal muscle in 1980 and subsequently classified as a kinase based on its ability to phosphorylate and inactivate Glycogen Synthase, the last step in Glycogen synthesis [28]. However, Glycogen Synthase was thought to exist as early as the 1960s [29]. This kinase was later isolated and characterized from rat skeletal muscle [30]. Three forms of Glycogen Synthase Kinase were further identified that are referred to as Glycogen Synthase Kinase 3, Glycogen Synthase Kinase 4, and Glycogen Synthase Kinase 5, which regulates Glycogen Synthase by producing different levels of phosphorylation [31]. Glycogen Synthase Kinase 5 is referred to as Casein Kinase-2 (CK2), which is a primer of Glycogen Synthase that is phosphorylated by GSK3 [32,33]. In the early 1990s, it was shown that there are two similar forms of GSK3, GSK3- α (GSK-3 α) and GSK3- β (GSK-3 β) [8,34]. GSK3 α and GSK3 β differ in their C and N terminals, however, they share 98% sequence homology in their catalytic domains resulting in 84% overall sequence homology [8]. GSK3 is a serine/threonine kinase which is constitutively active in resting cells from a variety of tissues [35,36]. GSK3 has been implicated in many cellular processes and is thought to phosphorylate over 50 substrates [6]. In the following, we will focus mainly on GSK3 β . Through recent advances in bioinformatic approaches, we have used the web service software from Pathway Linker to produce a link between GSK3 β and its signaling pathways (Figure 1) [37]. In addition to the protein signaling pathways, Table 1 represents signaling pathways where GSK3 β is significantly involved [37]. As can be seen in Figure 1 and Table 1, GSK3 β is involved in a diverse range of signaling pathways. Some of the classic pathways involved in inflammation and pain which are represented in Table 1 are the chemokine, B cell, opioid, leukocyte, and toll-like receptor signaling pathways.

Multiple groups have worked at identifying and characterizing the crystal structure of GSK3 β . The first crystallized structure of GSK3 β occurred in 2001 and provided insight into the mechanism by which the kinase is phosphorylated. The initial crystallization occurred in the unphosphorylated (apo) form of GSK3 β (PDB ID: 1I09) [38]. GSK3 β has a two domain kinase fold where the N-terminal end has a B-strand domain composed of 7 anti-parallel

beta strands and a C-terminal end with a conserved alpha helical domain (Figure 2A,2B). A few characteristics of the kinase that have been determined from the crystal structure are that the kinase has an ATP binding site, an activation loop, and a glycine-rich loop. However, the inhibitory phosphorylation of Serine-9 is not present due to the lack of electron density being visible on the residue. The structure of GSK3 β (PDB ID: 1Q5K) was later co-crystallized with the GSK3 β inhibitor AR-A014418 in 2003, which provided additional insight into the mechanism of inhibition [39]. The mechanism for inhibition is further discussed in the pharmacology of GSK3 section.

Regulation of GSK3

The regulation of GSK3 β has been extensively studied and reviewed [40,41]. There are different ways of regulating GSK3 β which occurs through phosphorylation of specific amino acid residues, by the formation of protein complexes with GSK3 β , and with pharmacological interventions.

The regulation of GSK3 β can occur through the phosphorylation of specific residues and the subsequent activation or inactivation of the kinase. Inactivation of GSK3 β can occur through phosphorylation of Serine-9 [8,42], Serine-389 [43], Threonine-390 [43], or Threonine-43 [44], while activation can occur through the phosphorylation of Tyrosine-216 [45]. Phosphorylation of the Serine-9 residue has been extensively studied and is a major mechanism to regulate GSK3 β activities by the inactivation of GSK3 β . Activation of three upstream signaling pathways are known to inhibit GSK3 β activity through phosphorylation of the Serine-9 residue including, the phosphatidylinositol 3-kinases (PI3K), the mammalian target of rapamycin (mTOR), and indirectly through the mitogen-activated protein kinase/extracellular signal-regulated kinases (MAPK/ERK) pathway [41]. The signals which lead to the downstream phosphorylation and inhibition of GSK3 β occurs by way of a diverse group of substances including, but not limited to, amino acids, growth factors, esters, and insulin [41].

GSK3 β pathways have drawn increased attention and the complexity of the pathways has been heavily studied in the field [3,46,47]. One of the first identified modulators of GSK3 β phosphorylation was AKT, which is also termed Protein Kinase B (PKB) and is downstream of the PI3K pathway [48]. Initially, insulin was identified to inhibit GSK3 β ; however, the mechanism and specificity were unclear [48-50]. In studies that examined the effects of insulin on purified Glycogen Synthases, it was shown that the effect on glycogen metabolism was mediated by Glycogen Synthase 3 [35,48,51]. Glycogen synthase kinase serine residues were later identified to be dephosphorylated by insulin in vivo [51]. It was not until the identification of GSK3 α and GSK3 β when it was determined that insulin negatively regulates GSK3 [52]. The importance of the phosphatidylinositol (PI) 3-kinase in the signaling pathway was demonstrated by showing that inhibition of PI3K reverses insulin induced GSK3 inhibition and that incubation with serine/threonine phosphatases reverses insulin's inhibitor effect [53]. Soon after, serine residues were identified as phosphorylation targets that mediate the inactivation of GSK3 following insulin administration which is facilitated by PKB. The serine residues which are phosphorylated and inactivated following insulin inhibition are Serine-21 for GSK3 α and Serine-9 for GSK3 β [48].

Two signaling pathways of GSK3 β that act as regulators of the kinase are mTOR and ERK. Glycogen synthase and Glycogen synthesis were first shown to be regulated through the mTOR pathway in human muscle cells. It was also shown that amino acid availability regulates glycogen synthesis through GSK3 β Serine-9 phosphorylation independently in the mTOR pathway [54]. Following the identification of mTOR as a regulator of GSK3 β , S6K was shown to be downstream of mTOR and to regulate GSK3 β phosphorylation [55]. These studies show that GSK3 β is regulated directly by S6K differently from how it is regulated in the PI3K pathway. Following the inhibition of AKT, S6K phosphorylates the Serine-9 residue of GSK-3 β in vivo [55]. Another regulator of GSK3 β which entails a different signaling pathway is the ERK pathway. This pathway is different from the PI3K and mTOR pathways in that ERK regulates GSK3 β through a priming mechanism. In hepatocellular carcinoma, it has been shown that GSK3 β is phosphorylated at the Threonine-43 residue following ERK activation. In response to threonine-43 phosphorylation, MAPK-activated protein kinase 1 (MAPKAP-K1/p90RSK) acts to phosphorylate the primed GSK3 β kinase at serine-9 residue rendering it inactive [44].

Another site of phosphorylation is the residue Tyrosine-216, which results in an increased activity of GSK3 β [45] (Figure 2C). This was identified by the substitution of the tyrosine site with a phenylalanine residue showing that only Tyrosine-216 is phosphorylated under native conditions. In the catalytic domain, Tyrosine-216 lies in the activation loop and phosphorylation is needed for activity [45]. The activation loop, where catalytic activity increases following phosphorylation of Tyrosine-216, is highlighted in Figure 2B. In *Dictyostelium*, it has been shown that ZAK1, a tyrosine kinase, activates and phosphorylates GSK3 β in vitro [56]. Phosphorylation of Tyrosine-216 has been shown to be increased following nerve growth factor (NGF) withdrawal and protein kinase C inhibition with staurosporine in vitro [57]. In a rat ischemic model, Tyrosine-216 phosphorylation is increased [57]. Lysophosphatidic acid (LPA) has been shown to phosphorylate Tyrosine-216 during neurite retraction [58]. Tyrosine-216 phosphorylation has been shown to occur through phospholipase C activation of Protein Tyrosine Kinase 2 Beta (Pyk2), which phosphorylates the tyrosine on GSK3 β and microtubule-associated proteins [59]. The upstream signaling pathways of Tyrosine-216 phosphorylation have been minimally studied compared to Serine-9 inhibition, and these studies indicate that tyrosine activation may play a role in the regulation of GSK3 β ; however, further studies are needed to examine the role of tyrosine phosphorylation in disease progression.

GSK3 β can also be regulated through the formation of protein complexes which occurs in both the Wnt and Hedgehog pathways [60, 61]. The Wnt pathway has been shown to play a role in tissue maintenance, cell-cell interactions, and dysfunction in signaling may lead to degenerative diseases [46]. Proteins which bind with GSK3 β to form an active or inactive complex are Axin and GSK3 binding protein (GBP), respectively [62]. In *Xenopus* embryos, it has been shown that the Wnt pathway is negatively regulated by the presence of Axin [63]. Through protein isolated from a rat cDNA library, it has been determined, in vitro, that the interaction between GSK3 β and beta-catenin is negatively regulated through Axin binding to GSK3 β in the Wnt pathway [62]. Axin is stabilized by the phosphorylation of GSK3 β , which causes an increase of Axin [64]. Briefly, GSK3 forms a complex with Axin and adenomatous polyposis coli (APC), both substrates of GSK3, which phosphorylate beta-

catenin leading to degradation in the absence of an initial Wnt ligand [65-67]. However, when a Wnt ligand is present, GSK3 does not form a complex with Axin and active GSK3 inhibits phosphorylation of beta-catenin preventing degradation of beta-catenin through the proteasome pathway [68,69]. These studies indicate the importance of GSK3 β complex formation in the Wnt pathway and the role of GSK3 β inhibition on signaling [70].

The hedgehog pathway is important in both normal development and the production of cancers [71,72]. GSK3 has been shown to be a negative regulator of the hedgehog pathway in drosophila through forming a complex with Protein Kinase A (PKA) for proteolytic processing of the DNA-binding protein, Cubitus interruptus (Ci) [61]. Briefly, a complex forms between PKA, GSK3, and casein kinase 1 (CK1) which binds to costal-2 (Cos2). Following binding to Cos2, the complex phosphorylates Ci causing an inhibitory effect on the pathway due to the phosphorylation [72]. The phosphorylation of Ci causes the proteolytic degradation from an active form to an inactive form [73]. The decrease in phosphorylation of Ci leads to a decrease in proteolytic processing producing an opposite effect [61]. These studies indicate the relevance of GSK3 β in complex formations and further work is needed to study the role in disease progression.

Pharmacology of GSK3

Aberrant regulation of GSK3 β has been implicated and studied in several disorders such as Alzheimer's disease, type 2 diabetes, and bipolar disorder [6,74-79]. Many pharmacological agents have been developed due to the involvement of GSK3 β in the different diseases with different mechanisms of action [80]. There have been six completed clinical trials involving inhibitors of GSK3 in Alzheimer's disease [81], hair loss [82], progressive supranuclear palsy [83,84], and bipolar disorder [85]. There are currently three clinical trials which are recruiting for bipolar disorder [86,87], spinal cord injuries and muscle atrophy [88]. In addition, there is a suspended clinical trial in patients with gliomas [89]. The broad spectrum of clinical trials indicates the importance of GSK3 in many pathological processes.

GSK3 β activity can be regulated by pharmacological interventions. The most extensively studied GSK3 β inhibitor is lithium chloride [90]. Within this context, lithium has been extensively studied as a regulator of GSK3 β signaling pathways in bipolar disorder [91]. While lithium chloride has been shown to be effective in treating bipolar disorder, high concentrations are needed for physiological and pharmacological effects [92]. Lithium was first shown to have an effect on GSK3 in the early 1990s [90]. GSK3 was identified as a target in intact cells and invitro showing the potential role of GSK3 in development [92]. In the nervous system, axonal growth has also shown to be decreased by lithium administration [93] and in a mouse model of degeneration [20]. Compared to other inhibitors, lithium chloride is a noncompetitive ATP inhibitor which competes with Mg²⁺ for association with the kinase and is most effective in vivo [94]. Lithium also has a high inhibitor constant, $K_i = 2\text{mM}$ [94,95]. Lithium compared to other inhibitors, at high doses can inhibit both GSK3 β and GSK3 α [96]. Also, lithium has been shown to indirectly activate AKT in neuronal cells which can consequently phosphorylate kinases other than GSK3 β and has also shown to be protective against glutamate excitotoxicity in vitro [97]. These studies point to the potential clinical and therapeutic effects of lithium and the lack of specificity for GSK3 β .

Two GSK3 β inhibitors of interest that utilize a different mechanism of inhibition other than lithium chloride are SB216763 and AR-A014418 (Figure 3A and Figure 3B). For both inhibitors, their mechanism of action is through binding in the ATP pocket of GSK3 β [98]. SB216763 is an anilinomaleimide with a K_i ranging from 10nM to 30nM for GSK3 α and in the presence of ATP inhibits GSK3 β activity by up to 96% [99]. AR-A014418 is a thiazole with a K_i of 38nM and inhibits GSK3 β with an $IC_{50}=104\pm 27$ nM. The inhibitor binds within the ATP pocket along the hinge/linker region where the nitro group engages the ATP pocket [39]. GSK3 α is also inhibited by these small molecule inhibitors; however the focus of this review is on the inhibition of GSK3 β . Both of these small molecule inhibitors are more selective and potent compared to lithium chloride, which may help in identifying the specific role of GSK3 β in different disease pathologies.

GSK3 β Inflammatory Signaling Pathways

Glycogen Synthase Kinase 3 has been identified as a target for inflammatory mediated diseases [6] and plays a key role in mediating inflammatory responses (see Table 1 for signaling pathways). The role of GSK3 β in inflammation was first shown by Martins and coworkers in 2005 [100]. They determined that following the development of inflammation, the kinase acts as a modulator for the expression of key pro-inflammatory and anti-inflammatory cytokines derived from monocytes and other peripheral blood cells to dampen inflammatory responses [100]. The mechanism by which GSK3 β attenuates inflammation has been hypothesized to be regulated, in part, through the nuclear translocation of the transcriptional factor CREB(cAMP Response Element-Binding Protein) [100]. GSK3 has been shown to have an inhibitory effect on CREB regulation resulting in decreased nuclear translocation of CREB [101]. The decreased translocation of CREB into the nucleus increases the expression of pro-inflammatory cytokines such as Interleukin-1-Beta (IL-1 β) and Tumor Necrosis Factor -1 alpha (TNF- α). Inhibition of GSK3 β increases CREB DNA binding activity, which increases the transcription and expression of anti-inflammatory cytokines (IL-10) [100,102,103]. In dendritic cells, GSK3 β is involved in TNF- α and IL-6 secretion [104]. These studies provide evidence for the importance of GSK3 activity in regulating pro- and anti-inflammatory response where by an increase in GSK3 β activity increases the production of pro-inflammatory cytokines while a decrease in GSK3 β activity results in the production of anti-inflammatory cytokines.

The mechanism by which of GSK3 regulates CREB translocation has been further elucidated in a model for intestinal inflammation. Following the development of inflammation, inhibition of GSK3 reduces the pro-inflammatory phenotype of Toll-like receptors [100]. In addition, inhibition of GSK3 modulates the transcriptional activity of both CREB and nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B), a master regulator of inflammation, in the intestinal immune cells [105]. The translocation of NF- κ B from the cytoplasm to the nucleus results in the transcription of pro-inflammatory genes such as IL-1 β , TNF- α , and IL-6 [106]. In a model of acute inflammation, inhibition of NF- κ B in leukocytes decreases inflammation [107] and adenoviral infection of human macrophages, which inhibits NF- κ B activation, decreases the production of TNF- α [108]. Interleukin-10, an anti-inflammatory cytokine, decreases the transcription of NF- κ B resulting in a decrease in the expression of pro-inflammatory cytokines [109]. The activation

of GSK3 β modulates the nuclear translocation of both NF- κ B and CREB by enabling CREB Binding Protein (CBP) to bind both transcriptional factors, which facilitates nuclear translocation and increases the production and transcription of pro-inflammatory cytokines. When GSK3 is inactivated, NF- κ B translocation is decreased while CREB transcription increases [101]. This results in a relative increase of CREB in the nucleus compared to NF- κ B and increases the binding of CBP to CREB. The increase of CBP binding to CREB produces an increase in the transcription of anti-inflammatory cytokines (e.g., IL-10) [100,103]. The importance of GSK3 in regulating anti-inflammatory cytokines through the NF- κ B pathway has been shown in GSK3 mouse knockouts [110]. In addition, it has been shown that inhibition of GSK3 can decrease NF- κ B activation in hepatocytes [111]. It has also been shown in hepatocytes that the inhibition of GSK3 β reduces NF- κ B activity, increases CREB transcription factor, and attenuates TNF- α mediated apoptosis [101]. These studies indicate the importance of CREB and NF- κ B transactivation through GSK3 in regulating the release of pro-inflammatory and anti-inflammatory cytokines (Figure 4).

Neuroinflammation and GSK3

Neuroinflammation is an inflammatory response that is characterized by glial activation and the production of inflammatory cytokines [112]. There are many diseases which are linked to the increased activation of glial cells and elevated pro-inflammatory cytokines.

Neuroinflammation has been implicated in multiple neurological disorders of the central nervous system (CNS) such as acquired immune deficiency syndrome (AIDS), stroke, and multiple sclerosis [113]. These disorders all share a common neuroinflammatory response; however, the etiologies of these disorders vary. GSK3 β has recently been shown to be involved in the activation of glial cells. In rat cortical glia, GSK3 β is expressed in both astrocytes and microglia and is activated following exposure to lipopolysaccharide (LPS) [114]. Following stimulation, pro-inflammatory cytokines are increased and inhibition of GSK3 β attenuates the production of pro-inflammatory cytokines (IL-1 β and TNF- α) and augments the production of anti-inflammatory cytokines (IL-10) in vitro [114]. In addition, GSK3 activation has been linked to the increase in glial cell proliferation [115].

Inflammation of the brain is isolated from the body through the blood brain barrier (BBB), where an increase in immune cell trafficking occurs following injury [116,117]. Originally, the CNS was thought to be protected from systematic inflammation, however, it is now established that multiple factors can contribute to a neuroinflammatory response [118]. The inflammatory response of the brain appears to be more tightly regulated than peripheral inflammation and regulation occurs through the activation of glial cells [119]. In the CNS, glial cells encompass nearly 75% of the overall cells where the majority of glial cells are astrocytes and oligodendrocytes while the rest are microglia cells [120]. These three types of glial cells, particularly microglia and astrocytes act as immune responders in the CNS.

Microglia cells were first established to be a different cell type compared to astrocytes and oligodendrocytes in the early 1900s [121]. Microglia cells act as macrophages of the nervous system in normal conditions [122]. They are considered to be resident macrophages even though they only consist of 15% of the cells in the CNS [123,124]. In the CNS, it has

been shown that microglia cells become activated in different pathological conditions and release pro-inflammatory cytokines (IL-1 β , IL-6, and TNF- α) and chemokines [125]. The role of microglia cells in facilitating the proliferation of immune cells has also been thoroughly studied [126,127].

Astrocytes, in regards to neuroinflammation, act as scavengers of the CNS and recycle excess neurotransmitters and ions. Dysregulation of astrocytes has been shown to play a role in the development of neurological diseases [128]. Under normal conditions, astrocytes regulate excess glutamate in the synaptic cleft preventing neurotoxicity [129,130]. Following the accumulation of pro-inflammatory cytokines in the CNS, astrocytes become activated and proliferate. The increase in astrocytic activation causes an increase in proliferation, which can be identified with the increase in glial fibrillary acidic protein (GFAP) [131]. Although GFAP is currently used for immune staining and Western blotting of astrocytes, it only identifies ~15% of the total cell population [132]. An in vitro model of metabolic injury shows that astrocytes release interleukin 1 (IL-1), IL-6, TNF- α and interferon gamma (IFN- γ) [133]. When a neuroinflammatory response ensues, glial cells become activated and produce pro-inflammatory cytokines such as TNF- α , IL-1 β , and IL-6 and chemokines [134,135]. Microglia cells act as the first responders to injury while astrocytes sustain the inflammatory response.

Neuroinflammation can be seen as both beneficial and detrimental. Some of the common themes involved in the beneficial aspects of neuroinflammation occur through neuroprotection and axonal regeneration. Following stroke, microglial cells act in response to injury to scavenge necrotic debris in the CNS [136]. This occurs from the release of pro-inflammatory cytokines almost immediately [112] and activated glial cells, which sense and respond to ATP gradients, act to scavenge excess neurotransmitters and dead cells [137]. The increase in astrocyte activation and proliferation produces the formation of a glial scar, isolating the damaged area from the rest of the CNS [118]. Acute inflammation is advantageous due to the short lived nature and minimization of neuronal damage and toxicity resulting from the release of inflammatory cytokines and chemokines [138]. In a mouse genetic model for Alzheimer's disease, it has been shown that neurotoxicity of β -Amyloid deposits is reduced through bone marrow derived microglia activation [139]. In addition, Nitric Oxide-induced neuronal damage is increased in mice deficient for TNF- α and TNF- α is required for microglia activation following injury [140]. In addition, in mice IL-6 is important for glial cell activation and is important for neuronal protection following injury to the CNS [141]. Following spinal cord injury, it has been shown that the injection of microglial cells into the site of injury is associated with the regrowth of axons through immune cytochemical detection [142]. In a double blind study with patients with MS, blocking of TNF- α produces an exacerbation of the condition [143]. These studies indicate that cytokine production and glial cell activation and proliferation following injury can act beneficially.

However, dysfunctional regulation of neuroinflammation can also be detrimental. The chronic activation of glial cells and elevation of pro-inflammatory cytokines have been linked to multiple disorders [144]. The development of neuroinflammation can occur multiples ways with different disease etiologies. The inflammatory response can be induced

from infection, injury, or an autoimmune disorder. Following the infection of human immunodeficiency virus type 1 (HIV), the disease progresses to Acquired Immune Deficiency Syndrome (AIDS) with the late onset of neurological dysfunction termed AIDS dementia complex (ADC) [145]. ADC is shown to affect roughly 80% of individuals who progress from HIV to AIDS [146]. The progression to ADC has similar mechanisms of other neurological disease through means of neuroinflammation mainly from the activation of glial cells in the CNS [147]. Microglial cells are the primary targets of HIV infection [148] and increases in microglial cells appear to associate with increased viral infection. Histological studies in the CNS from individuals with AIDS show an increase in the proliferation and activation of astrocytes and microglial cells leads to the increased release of IL-1 β , TNF- α , and IL-6, which promotes the activation and proliferation of the virus [149]. Through in vitro HIV exposure to human and rat astrocytes, it has been determined that astrocytes are involved through voltage gate and NMDA calcium channels in the progression to ADC [150]. It has further been shown that following ADC, nonviral cells produce proinflammatory cytokines in addition to the viral production of cells in the CNS [151].

GSK3 β has been studied in the context of ADC. Through genome wide mRNA and microRNA expression profiles of HIV patients with and without dementia, GSK3 β expression is down regulated in patients with dementia [152]. Lithium treatment of mice, in vivo, has been shown to protect the hippocampus from HIV induced neurotoxicity and in vitro lithium exposure prior to infection has shown to reduce HIV induced neurotoxicity [153]. In addition, low dose administration of lithium has been shown to improve the psychological impairment produced from HIV progression [154].

Injury, another inducer of neuroinflammation, can produce strokes (i.e., CNS ischemia), which is a common type of acute brain injury caused by an interruption in the blood supply to the brain where intracellular mechanisms such as inflammation can cause neuronal damage [155]. After the initial injury, macrophages infiltrate the BBB causing an additional inflammatory response to occur [113]. The inflammatory response causes the proliferation and activation of glial cells in the CNS leading to the production of cytokines [136]. Following a stroke, elevated levels of IL-6 and TNF- α in blood or cerebrospinal fluid occur with early clinical symptoms of deterioration [156]. In addition, it has been shown in stroke patients that ischemia causes an abundance of the proinflammatory cytokines IL-6 and TNF- α in peripheral blood cells [157]. Stroke patients have an elevated intrathecal production of proinflammatory cytokines and chemokines indicating there is an increase in glial cell activation [158].

GSK3 β has also been studied in the context of stroke. In vivo, following focal cerebral ischemia, GSK3 β inhibition has been shown to reduce infarct size [159]. In a rat transient middle cerebral artery occlusion model, pretreatment with lithium decreases infarct size and improves recovery through the increased migration of mesenchymal stem cells [160]. The mechanism by which lithium is beneficial to the treatment of stroke has been thought to occur through activation of the AKT pathway and subsequent phosphorylation of GSK3 β , resulting in the attenuation of glutamate excitotoxicity [97]. In addition, pretreatment with

lithium has shown to attenuate the dephosphorylation of GSK3 β induced through hypoxia in vivo [161].

Multiple Sclerosis (MS) is an autoimmune disorder of the CNS that leads to neurological disability due to axonal deterioration and the pathogenesis of the disorder has been linked to inflammatory elements of MS plaques [162,163]. Briefly, leukocytes infiltrate the CNS through the BBB causing the migration of microglial cells leading towards axonal dysfunction [164]. In post-mortem human brain samples of patients with MS, it has been shown that the cytokines and chemokines RANTES, MCP-1, MIP-1 α , and MIP1- β are differentially expressed in glial cells to increase inflammation [165]. TNF has also been shown to be in the lesions of patients with MS indicating an increase of proinflammatory cytokines [166]. Inflammation of the CNS causes the activation of astrocytes and microglial cells which have been targeted in MS. In Act1 deficient mice, it has been shown that astrocytes are necessary for leukocyte recruitment in the CNS in an autoimmune encephalomyelitis model, a model of MS [167]. Inflammatory genes have also been shown to be up regulated in MS plaques [168]. MS is different from other neuroinflammatory mediated diseases in that it originates from immune dysregulation compared to insult/injury of the CNS.

GSK3 β has also been studied in the context of MS. In experimental autoimmune encephalomyelitis (EAE), over expression of GSK3 β increases disease severity, and lithium pretreatment suppresses clinical symptoms and microglial activation in the spinal cord and post treatment promoted partial recovery [169]. In individuals with chronic progressive MS, GSK3 β has been shown to be over expressed [170]. Interleukin-17 producing cells, which have been shown to be increased in MS, are inhibited following GSK3 inhibition in an EAE model in the spinal cord [171]. These studies provide evidence that GSK3 β is important in disease progression and inhibition of the kinase may play a role in a potential therapeutic.

Alzheimer's disease (AD) is a neurodegenerative disease involving inflammation of the CNS leading to memory loss followed by dementia. It has been suggested that the main cause of AD is due to an abundance of β -Amyloid in the brain [172]. β -Amyloid plaques have been shown to increase the inflammatory response in the brain of Alzheimer's patients. Glial cells are known to surround Alzheimer's plaques and in vitro it has been shown that they release IL-1 and growth factors which are components of plaques [173,174]. In addition, astrocytes have also been shown to surround neuritic plaques in AD [175]. In an age-matched study, Alzheimer's patients have higher levels of TNF- α in sera indicating an inflammatory response [176]. Using a mouse model for AD, it has been shown that β -Amyloid plaques cause an inflammatory response and LPS stimulation further enhances the production of the pro-inflammatory cytokines IL-1 β , TNF- α and monocyte chemo attractant protein-1 [177].

GSK3 β has been extensively studied in the context of Alzheimer's disease. AD patients have been shown to have an increase in GSK3 β activity that correlates with an increase in neuronal death [178]. It has been shown, in vitro, that GSK3 β inhibition with lithium treatment blocks the production of β -Amyloid [179]. In cultured rat cortical neurons, lithium protects cells from β -Amyloid induced death and there is a decrease in tau phosphorylation, a process that occurs in response to β -Amyloid accumulation [180]. This was further

validated with chronic lithium pretreatment on β -Amyloid induced cerebellar cell death [181]. Clinical studies have also been conducted to determine the benefits of lithium treatment in patients with AD. In elderly patients with both AD and bipolar disorder, chronic lithium treatment has shown to decrease AD symptoms to that seen in the general population [182]. Furthermore, it has been shown that chronic lithium treatment reduces the rate of dementia in a nationwide study [183]. These studies indicate the importance of GSK3 β in cognition and neuroinflammation.

Neuroinflammation and Pathological Pain

Glia activation and the subsequent release of proinflammatory cytokines play crucial roles in the development and maintenance of pathological pain [184-186]. Microglia and astrocytes are reactivated in almost every animal model of pathological pain [187, 188], including neuropathic pain induced by nerve injury [189,190], inflammation induced by complete Freund's adjuvant [185], surgical incision [191], and morphine tolerance [192]. These are accompanied with elevated levels of proinflammatory cytokines [193,194] and an increased expression of proinflammatory cytokines in microglia and astrocytes in the spinal dorsal horn [195-197], suggesting that the increased proinflammatory cytokines come from glial cells. Intrathecal administration of IL-1 β and TNF- α in normal rats enhances both the acute response and the wind-up activity of dorsal horn neurons and mechanical allodynia and hyperalgesia [198,199]. Suppression of astrocyte and microglial activation with the glial inhibitor, propentofylline, or inhibition of microglia activation by minocycline, results in attenuation of hyperalgesia induced by nerve injury, which is associated with decreased expression of the cytokines IL-1 β , IL-6 and TNF α in vivo [194,200,201]. Similarly, treatments with antagonists of IL-1 β , IL-6 and TNF α reduced hypersensitivity induced by inflammation, nerve injury or morphine tolerance. Besides the release pro-inflammatory cytokines, we and other have shown that activation of astrocytes is associated with dysfunction of glial glutamate transporters [202-204]. Down regulation of glial glutamate transporters in the spinal dorsal horn contributes to the genesis of many types of pathological pain including neuropathic pain induced by nerve injury [202,205,206], chemotherapy [207,208] and morphine tolerance [202,209]. We have demonstrated that impaired glutamate uptake by glial glutamate transporters is a key contributing factor to strengthening AMPA and NMDA receptor activation in the spinal sensory neurons [206,210-213]. Deficiency in glial glutamate uptake results in decreases in GABAergic synaptic strength due to impairment in the GABA synthesis through the glutamate-glutamine cycle [214]. Hence, the integrity of glial GTs is critical to maintain synaptic excitatory-inhibitory homeostasis and normal nociception in the spinal dorsal horn. Glial glutamate transporters appear to be regulated by neuroinflammation processes induced by nerve injury. Suppression of glial activation and pro-inflammatory cytokine production with propentofylline or minocycline up-regulates mRNA and protein expression of glial glutamate transporters in the spinal dorsal horn and ameliorates the nerve-injury-induced allodynia [201,204,215,216]. Therefore, identifying molecules that can suppress neuroinflammation has a great potential to open a new door to alleviate pathological pain.

Given the fact that the role of GSK3 in neuroinflammatory diseases in the CNS has been extensively studied and neuroinflammation is a crucial mechanism underlying the genesis of

pathological pain, it is surprising that there are only a handful of papers reporting the effects of pharmacological inhibition of GSK3 β on spinal nociceptive processing.

The first report of GSK3 β inhibition on spinal nociceptive processing has been shown in morphine-tolerant rats [217]. Parkitina and coworkers (2006) have shown that GSK3 β inhibition alters the tolerance to morphine in the dorsal lumbar of the spinal cord. Intra thecal inhibition of GSK3 β (SB216763) has shown to decrease pharmacological tolerance to morphine in a dose-dependent manner whereas GSK3 β inhibition of naïve rats has no effect determined from the tail flick test. Tolerance to morphine is associated with an increase in active GSK3 β where chronic intrathecal inhibitor administration increases phosphorylation at the Serine-9 residue of GSK3 β and decreases tolerance. Intrathecal inhibitor administration has shown to have no effect on increasing the phosphorylation of the Serine-9 residue or have analgesic effects in naïve rats [217].

The next report of GSK3 β inhibition on pain processing has been shown in mouse models of acute nociception through acetic acid induced abdominal constrictions and formalin induced nociception [7]. Martins and coworkers (2009) have shown that pharmacological inhibition of GSK3 β can have antinociceptive effects. They have shown that intraperitoneal pretreatment of a GSK3 β inhibitor (AR-A014418) prior to acetic-acid induced abdominal constrictions reduces writhings. They have also shown that pretreatment with a GSK3 β inhibitor by intraperitoneal, intraplantar, and intrathecal injection reduces licking frequency, a measure of nociception, following formalin induced nociception. Lastly, through intrathecal co-administration of the GSK3 β inhibitor with glutamate, NMDA, trans-ACPD, TNF- α , or IL-1 β there is a decrease in cytokine induced biting [7]. This study indicates that pharmacological inhibition of GSK3 β may play a role in nociception and pain.

The most recent report of GSK3 β inhibition on pain processing has been shown in a mouse model of neuropathic pain through peripheral nerve injury [5]. Martins and coworkers (2012) have shown that intraperitoneal administration of a GSK3 β inhibitor (AR-A014418) produces antihyperalgesic effects and decreases the proinflammatory cytokines IL-1 β and TNF- α in the lumbar portion of the spinal cord (Lumbar 1 to Lumbar 6). They have also shown that following the development of mechanical hyperalgesia, a single intraperitoneal administration of a GSK3 β inhibitor attenuates mechanical and thermal hyperalgesia. In addition, they have shown that chronic inhibition of serotonin synthesis prior to GSK3 β inhibition prevents the decrease in mechanical allodynia. While pharmacological inhibition of GSK3 β has been shown to reduce hyperalgesia induced by nerve injury [5], it remains unknown if inhibition of GSK3 β can prevent the development of allodynia following nerve injury. In an adult rat (Sprague Dawley) model of neuropathic pain induced by partial sciatic nerve ligation [206], with the same inhibitor (AR-A014418) and concentration (0.3 mg/kg), we found that chronic intraperitoneal administration from the day of surgery (1 injection/day) for 8 days significantly attenuates the development of mechanical allodynia induced by partial sciatic nerve ligation (Figure 5). These data suggest that altered GSK3 β activities may contribute to the development of neuropathic pain.

We further investigated possible changes of GSK3 β activities in the spinal dorsal horn in neuropathic rats induced by partial sciatic nerve ligation through immune histochemical

techniques. Eight days following peripheral nerve injury, we found that there is a decrease in phosphorylated GSK3 β on the lesion side compared to the uninjured side and sham operated rat (Figure 6). We also demonstrated that phosphorylated and total GSK3 β is localized to both astrocytes and neuronal cells (Figure 7). These data indicate that increased GSK3 β activities in the spinal dorsal horn may contribute to the genesis of neuropathic pain induced by sciatic nerve injury. Together with findings by others, these data suggest that GSK3 β may be a potential target for the development of analgesics for the treatment of neuropathic pain.

Conclusion

Glycogen Synthase Kinase 3 β has been linked to the development and progression of multiple disease entities. Following the initial identification of GSK3 β , significant strides have been made in understanding the structure, regulation, pharmacology, and diseases linked with the kinase. GSK3 β is a common target in inflammation of the CNS which has been associated with many diseases such as Alzheimer's disease, AIDS dementia complex, and stroke. Inhibition of GSK3 β has been shown to alleviate multiple symptoms and the progression of these diseases.

The role of GSK3 β in pathological pain has recently emerged. The development and maintenance of pathological pain is associated with changes in GSK3 β activities. Inhibition of GSK3 β activities can prevent the development and reverse the existence of neuropathic pain. Further studies are needed to understand the upstream pathways regulating GSK3 β activities and the downstream signaling pathways used by GSK3 β to alter spinal sensory processing, which will potentially lead to the use of GSK3 β as a novel target for the development of analgesics.

Acknowledgments

This project was supported by NIH RO1 grant NS064289 to HRW.

References

1. Hanks SK, Hunter T. Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. *The FASEB Journal*. 1995; 9:576–96.
2. Hanger DP, Hughes K, Woodgett JR, Brion JP, Anderton BH. Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: Generation of paired helical filament epitopes and neuronal localisation of the kinase. *Neurosci Lett*. 1992; 147:58–62. [PubMed: 1336152]
3. Cohen P, Frame S. The renaissance of GSK3. *Nat Rev Mol Cell Biol*. 2001; 2:769–776. [PubMed: 11584304]
4. Cantley LC. The phosphoinositide 3-kinase pathway. *Science Signalling*. 2002; 296:1655–1657.
5. Mazzardo ML, Martins DF, Stramosk J, Cidral-Filho FJ, Santos AR. Glycogen Synthase Kinase 3-Specific Inhibitor AR-A014418 Decreases Neuropathic Pain in Mice: Evidence for The Mechanisms of Action. *Neuroscience*. 2012; 226:411–420. [PubMed: 23000630]
6. Jope RS, Yuskaitis CJ, Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. *Neurochem Res*. 2007; 32:577–595. [PubMed: 16944320]
7. Martins DF, Rosa AO, Gadotti VM, Mazzardo ML, Nascimento FP. The antinociceptive effects of AR-A014418, a selective inhibitor of glycogen synthase kinase-3 beta, in mice. *The Journal of Pain*. 2011; 12:315–322. [PubMed: 20705523]
8. Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3/Factor A. *EMBO J*. 1990; 9:2431–2438. [PubMed: 2164470]

9. Ferrer I, Barrachina M, Puig B. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. *Acta neuropathol.* 2002; 104:583–591. [PubMed: 12410379]
10. Shiurba RA, Ishiguro K, Takahashi M, Sato K, Spooner ET, et al. Immunocytochemistry of tau phosphoserine 413 and tau protein kinase I in Alzheimer pathology. *Brain Res.* 1996; 737:119–132. [PubMed: 8930358]
11. Mandelkow EM, Drewes G, Biernat J, Gustke N, Van Lint J, et al. Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-associated protein tau. *FEBS Letters.* 1992; 314:315–321. [PubMed: 1334849]
12. Hernández F, Pérez M, Lucas JJ, Mata AM, Bhat R, et al. Glycogen Synthase Kinase-3 Plays a Crucial Role in Tau Exon 10 Splicing and Intranuclear Distribution of SC35: IMPLICATIONS FOR ALZHEIMER'S DISEASE. *J Biol Chem.* 2004; 279:3801–3806. [PubMed: 14602710]
13. Souza RP, Romano-Silva MA, Lieberman JA, Meltzer HY, Wong AH, et al. Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response. *Psychopharmacology.* 2008; 200:177–186. [PubMed: 18500637]
14. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA, et al. Convergent evidence for impaired AKT1-GSK3 β signaling in schizophrenia. *Nature genetics.* 2004; 36:131–137. [PubMed: 14745448]
15. Peterson JW, Bö L, Mörk S, Chang A, Trapp BD. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. *Annals of neurology.* 2001; 50:389–400. [PubMed: 11558796]
16. Kermode AG, Thompson AJ, Tofts P, MacManus DG, Kendall BE. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis Pathogenetic and clinical implications. *Brain.* 1990; 113:1477–1489. [PubMed: 2245307]
17. Thompson KA, McArthur JC, Wesselingh SL. Correlation between neurological progression and astrocyte apoptosis in HIV-associated dementia. *Ann Neurol.* 2001; 49:745–752. [PubMed: 11409426]
18. McArthur JC. HIV dementia: an evolving disease. *J Neuroimmunol.* 2004; 157:3–10. [PubMed: 15579274]
19. Stolp HB, Dziegielewska KM. Review: Role of developmental inflammation and blood–brain barrier dysfunction in neurodevelopmental and neurodegenerative diseases. *Neuropathol Appl Neurobiol.* 2009; 35:132–146. [PubMed: 19077110]
20. Noble W, Planel E, Zehr C, Olm V, Meyerson J, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. *Proc Natl Acad Sci USA.* 2005; 102:6990–6995. [PubMed: 15867159]
21. Martinez A, Perez DI. GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease? *J Alzheimers Dis.* 2008; 15:181–191. [PubMed: 18953107]
22. Martinez A. Preclinical efficacy on GSK-3 inhibitors: Towards a future generation of powerful drugs. *Medicinal research reviews.* 2008; 28:773–796. [PubMed: 18271054]
23. Lipina TV, Kaidanovich-Beilin O, Patel S, Wang M, Clapcote SJ, et al. Genetic and pharmacological evidence for schizophrenia-related Disc1 interaction with GSK-3. *Synapse.* 2011; 65:234–248. [PubMed: 20687111]
24. Scholz J, Woolf CJ. Can we conquer pain? *Nat Neurosci.* 2002; 5:1062–1067. [PubMed: 12403987]
25. Woolf CJ. Evidence for a central component of post-injury pain hypersensitivity. *Nature.* 1983; 306:686–688. [PubMed: 6656869]
26. Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. *Science.* 2000; 288:1765–1768. [PubMed: 10846153]
27. Woolf CJ, Shortland P, Coggeshall RE. Peripheral nerve injury triggers central sprouting of myelinated afferents. *Nature.* 1992; 355:75–78. [PubMed: 1370574]
28. Embi N, Rylatt DB, Cohen P. Glycogen Synthase Kinase-3 from Rabbit Skeletal Muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. *Eur J Biochem.* 1980; 107:519–527. [PubMed: 6249596]

29. Friedman DL, Larner J. Studies on UDPG- α -Glucan Transglucosylase. III. Interconversion of Two Forms of Muscle UDPG- α -Glucan Transglucosylase by a Phosphorylation-Dephosphorylation Reaction Sequence. *Biochemistry*. 1963; 2:669–675. [PubMed: 14075096]
30. Schlender KK, Beebe SJ, Willey JC, Lutz SA, Reimann EM. Isolation and characterization of cyclic AMP-independent glycogen synthase kinase from rat skeletal muscle. *Biochem Biophys Acta*. 1980; 615:324–340. [PubMed: 6251890]
31. Cohen P, Yellowlees D, Aitken A, Donella-Deana A, Hemmings BA. Separation and Characterisation of Glycogen Synthase Kinase 3, Glycogen Synthase Kinase 4 and Glycogen Synthase Kinase 5 from Rabbit Skeletal Muscle. *Eur J Biochem*. 1982; 124:21–35. [PubMed: 6282589]
32. Picton C, Aitken A, Bilham T, Cohen P. Multisite Phosphorylation of Glycogen Synthase from Rabbit Skeletal Muscle. *Eur J Biochem*. 1982; 124:37–45. [PubMed: 6806097]
33. Woodgett JR, Cohen P. Multisite phosphorylation of glycogen synthase: Molecular basis for the substrate specificity of glycogen synthase kinase-3 and casein kinase-II (glycogen synthase kinase-5). *Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology*. 1984; 788:339–347.
34. Woodgett JR. cDNA cloning and properties of glycogen synthase kinase-3. *Methods In Enzymol*. 1991; 200:564–577. [PubMed: 1659660]
35. Sutherland C, Leighton IA, Cohen P. Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. *Biochem J*. 1993; 296:15–19. [PubMed: 8250835]
36. Woodgett JR. Regulation and functions of the glycogen synthase kinase-3 subfamily. *Semin Cancer Biol*. 1994; 5:269–275. [PubMed: 7803763]
37. Farkas IJ, Szántó VÁ, Korcsmáros T. Linking proteins to signaling pathways for experiment design and evaluation. *PloS one*. 2012; 7:e36202. [PubMed: 22558382]
38. Ter Haar E, Coll JT, Austen DA, Hsiao HM, Swenson L, et al. Structure of GSK3 β reveals a primed phosphorylation mechanism. *Nat Struct Biology*. 2001; 8:593–596.
39. Bhat R, Xue Y, Berg S, Hellberg S, Ormö M, et al. Structural Insights and Biological Effects of Glycogen Synthase Kinase 3-specific Inhibitor AR-A014418. *J Biol Chem*. 2003; 278:45937–45945. [PubMed: 12928438]
40. Grimes CA, Jope RS. The multifaceted roles of glycogen synthase kinase 3 β in cellular signaling. *Progress in Neurobiology*. 2001; 65:391–426. [PubMed: 11527574]
41. Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery. *Biochemical Journal*. 2001; 359:1–16. [PubMed: 11563964]
42. Sutherland C, Leighton IA, Cohen P. Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. *Biochem J*. 1993; 296:15–19. [PubMed: 8250835]
43. Thornton TM, Pedraza-Alva G, Deng B, Wood CD, Aronshtam A, et al. Phosphorylation by p38 MAPK as an Alternative Pathway for GSK3 {beta} Inactivation. *Science Signalling*. 2008; 320:667–670.
44. Ding Q, Xia W, Liu JC, Yang JY, Lee DF, et al. Erk associates with and primes GSK-3 β for its inactivation resulting in upregulation of β -catenin. *Molecular cell*. 2005; 19:159–170. [PubMed: 16039586]
45. Hughes K, Nikolakaki E, Plyte SE, Totty NF, Woodgett JR. Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. *The EMBO journal*. 1993; 12:803–808. [PubMed: 8382613]
46. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. *Annu Rev Cell Dev Biol*. 2004; 20:781–810. [PubMed: 15473860]
47. Wu D, Pan W. GSK3: a multifaceted kinase in Wnt signaling. *Trends biochem sci*. 2010; 35:161–68. [PubMed: 19884009]
48. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. *Nature*. 1995; 378:785–789. [PubMed: 8524413]

49. Cohen P. The coordinated control of metabolic pathways by broad-specificity protein kinases and phosphatases. *Curr top cellular regul.* 1985; 27:23–37.
50. Cohen P. The hormonal control of glycogen metabolism in mammalian muscle by multivalent phosphorylation. *Biochem Soc Trans.* 1979; 7:459–480. [PubMed: 221283]
51. Parker PJ, Caudwell FB, Cohen P. Glycogen synthase from rabbit skeletal muscle; effect of insulin on the state of phosphorylation of the seven phosphoserine residues in vivo. *Eur J Biochem.* 1983; 130:227–234. [PubMed: 6402364]
52. Hughes K, Ramakrishna S, Benjamin WB, Woodgett JR. Identification of multifunctional ATP-citrate lyase kinase as the α -isoform of glycogen synthase kinase-3. *Biochem J.* 1992; 15:309–314. [PubMed: 1332698]
53. Cross DA, Alessi DR, Vandenheede JR, McDowell HE, Hundal HS, et al. The inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor 1 in the rat skeletal muscle cell line L6 is blocked by wortmannin, but not by rapamycin: evidence that wortmannin blocks activation of the mitogen-activated protein kinase pathway in L6 cells between Ras and Raf. *Biochem J.* 1994; 303:21–26. [PubMed: 7945242]
54. Armstrong JL, Bonavaud SM, Toole BJ, Yeaman SJ. Regulation of Glycogen Synthesis by Amino Acids in Cultured Human Muscle Cells. *J Biol Chem.* 2001; 276:952–956. [PubMed: 11013237]
55. Zhang HH, Lipovsky AI, Dibble CC, Sahin M, Manning BD. S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. *Molecular cell.* 2006; 24:185–197. [PubMed: 17052453]
56. Kim L, Liu J, Kimmel AR. The Novel Tyrosine Kinase ZAK1 Activates GSK3 to Direct Cell Fate Specification. *Cell.* 1999; 99:399–408. [PubMed: 10571182]
57. Bhat RV, Shanley J, Correll MP, Fieles WE, Keith RA, et al. Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3 β in cellular and animal models of neuronal degeneration. *Proc Natl Acad Sci.* 2000; 97:11074–11079. [PubMed: 10995469]
58. Sayas CL, Moreno-Flores MT, Avila J, Wadosell F. The neurite retraction induced by lysophosphatidic acid increases Alzheimer's disease-like Tau phosphorylation. *J Biol Chem.* 1999; 274:37046–37052. [PubMed: 10601262]
59. Sayas CL, Ariaens A, Ponsioen B, Moolenaar WH. GSK-3 is activated by the tyrosine kinase Pyk2 during LPA1-mediated neurite retraction. *Mol biol cell.* 2006; 17:1834–1844. [PubMed: 16452634]
60. Salic A, Lee E, Mayer L, Kirschner MW. Control of beta-catenin stability: reconstitution of the cytoplasmic steps of the wnt pathway in *Xenopus* egg extracts. *Molecular cell.* 2000; 5:523–532. [PubMed: 10882137]
61. Jia J, Amanai K, Wang G, Tang J, Wang B, et al. Shaggy/GSK3 antagonizes Hedgehog signalling by regulating Cubitus interruptus. *Nature.* 2002; 416:548–552. [PubMed: 11912487]
62. Ikeda S, Kishida S, Yamamoto H, Murai H, Koyama S, et al. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3[beta] and [beta]-catenin and promotes GSK-3[beta]-dependent phosphorylation of [beta]-catenin. *EMBO J.* 1998; 17:1371–1384. [PubMed: 9482734]
63. Zeng L, Fagotto F, Zhang T, Hsu W, Vasicek TJ, et al. The Mouse Fused Locus Encodes Axin, an Inhibitor of the Wnt Signaling Pathway That Regulates Embryonic Axis Formation. *Cell.* 1997; 90:181–192. [PubMed: 9230313]
64. Yamamoto H, Kishida S, Kishida M, Ikeda S, Takada S, et al. Phosphorylation of Axin, a Wnt Signal Negative Regulator, by Glycogen Synthase Kinase-3 β Regulates Its Stability. *J Biol Chem.* 1999; 274:10681–10684. [PubMed: 10196136]
65. Amit S, Hatzubai A, Birman Y, Andersen JS, Ben-Shushan E, et al. Axin-mediated CKI phosphorylation of β -catenin at Ser 45: a molecular switch for the Wnt pathway. *Genes Dev.* 2002; 16:1066–1076. [PubMed: 12000790]
66. Kimelman D, Xu W. β -Catenin destruction complex: insights and questions from a structural perspective. *Oncogene.* 2006; 25:7482–7491. [PubMed: 17143292]
67. Kitagawa M, Hatakeyama S, Shirane M, Matsumoto M, Ishida N, et al. An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of β -catenin. *EMBO j.* 1999; 18:2401–2410. [PubMed: 10228155]

68. Polakis P. Wnt signaling and cancer. *Genes Dev.* 2000; 14:1837–1851. [PubMed: 10921899]
69. Hart MJ, de los Santos R, Albert IN, Rubinfeld B, Polakis P. Downregulation of β -catenin by human Axin and its association with the APC tumor suppressor, β -catenin and GSK3. *Curr Biol.* 1998; 8:573–581. [PubMed: 9601641]
70. Metcalfe C, Bienz M. Inhibition of GSK3 by Wnt signalling—two contrasting models. *J Cell Sci.* 2011; 124:3537–3544. [PubMed: 22083140]
71. Fan CM, Porter JA, Chiang C, Chang DT, Beachy PA, et al. Long-range sclerotome induction by sonic hedgehog: Direct role of the amino-terminal cleavage product and modulation by the cyclic AMP signaling pathway. *Cell.* 1995; 81:457–465. [PubMed: 7736597]
72. Aikin RA, Ayers KL, Thérond PP. The role of kinases in the Hedgehog signalling pathway. *EMBO Rep.* 2008; 9:330–336. [PubMed: 18379584]
73. Chen Y, Gallaher N, Goodman RH, Smolik SM. Protein kinase A directly regulates the activity and proteolysis of cubitus interruptus. *Proc Natl Acad Sci.* 1998; 95:2349–2354. [PubMed: 9482888]
74. Hernández F, Nido JD, Avila J, Villanueva N. GSK3 inhibitors and disease. *Mini rev med chem.* 2009; 9:1024–1029. [PubMed: 19689399]
75. Beurel E. Regulation by glycogen synthase kinase-3 of inflammation and T cells in CNS diseases. *Front mol neurosci.* 2011; 4:18. [PubMed: 21941466]
76. Kwok JB, Hallupp M, Loy CT, Chan DK, Woo J, et al. GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. *Ann neurol.* 2005; 58:829–839. [PubMed: 16315267]
77. Eldar-Finkelman H. Glycogen synthase kinase 3: an emerging therapeutic target. *Trends Mol Med.* 2002; 8:126–132. [PubMed: 11879773]
78. Martinez A, Castro A, Dorronsoro I, Alonso M. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. *Med Res Rev.* 2002; 22:373–384. [PubMed: 12111750]
79. Rowe MK, Wiest C, Chuang DM. GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. *Neurosci Biobehav Rev.* 2007; 31:920–931. [PubMed: 17499358]
80. Forde JE, Dale TC. Glycogen synthase kinase 3: a key regulator of cellular fate. *Cell Mol Life Sci.* 2007; 64:1930–1944. [PubMed: 17530463]
81. ClinicalTrials.gov. Safety Study of a Glycogen Synthase Kinase 3 (GSK3) Inhibitor in Patients With Alzheimer's Disease. 2009
82. ClinicalTrials.gov. The Efficacy and Safety of Topical Valproic Acid in Preventing Hair Loss. 2012
83. ClinicalTrials.gov. Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine). 2012
84. Clinical Trials.gov. Safety, Tolerability, Efficacy of Two Different Oral Doses of NP 031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy (Tauros). 2012
85. ClinicalTrials.gov. Investigation of Lithium on Signal Transduction, Gene Expression and Brain Myo-Inositol Levels in Manic Patients. 2009
86. Clinical Trials.gov. Simvastatin Augmentation of Lithium Treatment in Bipolar Depression. 2012
87. ClinicalTrials.gov. Neural Correlates for Therapeutic Mechanisms of Lithium in Bipolar Disorder. 2012
88. ClinicalTrials.gov. Characterization of the Changes in the Signalling Pathways During Spinal Cord Injury-induced Skeletal Muscle Atrophy. 2012
89. ClinicalTrials.gov. A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas. 2012
90. Klein PS, Melton DA. A Molecular Mechanism for the Effect of Lithium on Development. *Proc Natl Acad Sci USA.* 1996; 93:8455–8459. [PubMed: 8710892]
91. Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. *Arch Gen Psychiatry.* 2000; 57:481–489. [PubMed: 10807488]

92. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics Wingless signalling in intact cells. *Curr Biol.* 1996; 6:1664–1669. [PubMed: 8994831]
93. Takahashi M, Yasutake K, Tomizawa K. Lithium inhibits neurite growth and tau protein kinase I/ glycogen synthase kinase-3 β -dependent phosphorylation of juvenile tau in cultured hippocampal neurons. *J neurochem.* 1999; 73:2073–2083. [PubMed: 10537067]
94. Ryves WJ, Harwood AJ. Lithium Inhibits Glycogen Synthase Kinase-3 by Competition for Magnesium. *Biochem Biophys Res Commun.* 2001; 280:720–725. [PubMed: 11162580]
95. Ryves WJ, Dajani R, Pearl L, Harwood AJ. Glycogen synthase kinase-3 inhibition by lithium and beryllium suggests the presence of two magnesium binding sites. *Biochem Biophys Res Commun.* 2002; 290:967–972. [PubMed: 11798168]
96. Phiel CJ, Klein PS. Molecular targets of lithium action. *Annu rev pharmacol toxicol.* 2001; 41:789–813. [PubMed: 11264477]
97. Chalecka-Franaszek E, Chuang DM. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. *Proc Natl Acad Sci.* 1999; 96:8745–8750. [PubMed: 10411946]
98. Jacobs KM, Bhawe SR, Ferraro DJ, Jaboin JJ, Hallahan DE, et al. GSK-3: A Bifunctional Role in Cell Death Pathways. *Int J Cell Biol.* 2012 E pub2012.
99. Coghlan MP, Culbert AA, Cross DA, Corcoran SL, Yates JW, et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. *Chem Biol.* 2000; 7:793–803. [PubMed: 11033082]
100. Martin M, Rehani K, Jope RS, Michalek SM. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. *Nat Immunol.* 2005; 6:777–784. [PubMed: 16007092]
101. Götschel F, Kern C, Lang S, Sparna T, Markmann C, et al. Inhibition of GSK3 differentially modulates NF- κ B, CREB, AP-1 and β -catenin signaling in hepatocytes, but fails to promote TNF- α -induced apoptosis. *Exp Cell Res.* 2008; 314:1351–1366. [PubMed: 18261723]
102. Grimes CA, Jope RS. CREB DNA binding activity is inhibited by glycogen synthase kinase-3 β and facilitated by lithium. *J Neurochem.* 2001; 78:1219–1232. [PubMed: 11579131]
103. Wen AY, Sakamoto KM, Miller LS. The Role of the Transcription Factor CREB in Immune Function. *J Immunol.* 2010; 85:6413–6419. [PubMed: 21084670]
104. Rodionova E, Conzelmann M, Maraskovsky E, Hess M, Kirsch M, et al. GSK-3 mediates differentiation and activation of proinflammatory dendritic cells. *Blood.* 2007; 109:1584–1592. [PubMed: 17032918]
105. Hofmann C, Dunger N, Schölmerich J, Falk W, Obermeier F. Glycogen synthase kinase 3- β : A master regulator of toll-like receptor-mediated chronic intestinal inflammation. *Inflamm Bowel Dis.* 2010; 16:1850–1858. [PubMed: 20848477]
106. Tak PP, Firestein GS. Firestein, NF-kappaB: a key role in inflammatory diseases. *J Clin Invest.* 2001; 107:7–11. [PubMed: 11134171]
107. Lawrence T, Gilroy DW, Colville-Nash PR, Willoughby DA. Possible new role for NF-[kappa]B in the resolution of inflammation. *Nat Med.* 2001; 7:1291–1297. [PubMed: 11726968]
108. Foxwell B, Browne K, Bondeson J, Clarke C, de Martin R, et al. Efficient adenoviral infection with I κ B α reveals that macrophage tumor necrosis factor α production in rheumatoid arthritis is NF- κ B dependent. *Proc Natl Acad Sci USA.* 1998; 95:8211–8215. [PubMed: 9653166]
109. Driessler F, Venstrom K, Sabat R, Asadullah K, Schottelius AJ. Molecular mechanisms of interleukin-10-mediated inhibition of NF- κ B activity: a role for p50. *Clin Exp Immunol.* 2004; 135:64–73. [PubMed: 14678266]
110. Antoniv TT, Ivashkiv LB. Interleukin-10-induced gene expression and suppressive function are selectively modulated by the PI3K-Akt-GSK3 pathway. *Immunology.* 2011; 132:567–577. [PubMed: 21255011]
111. Schwabe RF, Brenner DA. Role of glycogen synthase kinase-3 in TNF- α -induced NF- κ B activation and apoptosis in hepatocytes. *Am J Physiol Gastrointest Liver Physiol.* 2002; 283:G204–G211. [PubMed: 12065308]
112. Streit WJ, Mrak RE, Griffin WS. Microglia and neuroinflammation: a pathological perspective. *J Neuroinflammation.* 2004; 1:14. [PubMed: 15285801]

113. de Vries HE, Kuiper J, de Boer AG, Van Berkel TJ, Breimer DD. The blood-brain barrier in neuroinflammatory diseases. *Pharmacol Rev.* 1997; 49:143–155. [PubMed: 9228664]
114. Green HF, Nolan YM. GSK-3 mediates the release of IL-1 β , TNF- α and IL-10 from cortical glia. *Neurochem Int.* 2012; 61:666–671. [PubMed: 22796213]
115. Beurel E, Michalek SM, Jope RS. Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3). *Trends Immunol.* 2010; 31:24–31. [PubMed: 19836308]
116. Lampson LA. Molecular bases of the immune response to neural antigens. *Trends in Neurosciences.* 1987; 10:211–216.
117. Roberts TK, Buckner CM, Berman JW. Leukocyte transmigration across the blood-brain barrier: perspectives on neuroAIDS. *Front Biosci.* 2010; 15:478–536.
118. Lucas SM, Rothwell NJ, Gibson RM. The role of inflammation in CNS injury and disease. *Br J Pharmacol.* 2006; 147(Suppl 1):S232–S240. [PubMed: 16402109]
119. Consilvio C, Vincent AM, Feldman EL. Neuroinflammation, COX-2, and ALS—a dual role? *Exp Neurol.* 2004; 187:1–10. [PubMed: 15081582]
120. Moalem G, Tracey DJ. Immune and inflammatory mechanisms in neuropathic pain. *Brain Res Rev.* 2006; 51:240–264. [PubMed: 16388853]
121. del Rio-Hortega P. Art and artifice in the science of histology. *Histopathology.* 1993; 22:515–525. [PubMed: 8354484]
122. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. *Science.* 2005; 308:1314–1318. [PubMed: 15831717]
123. Rivest S. Regulation of innate immune responses in the brain. *Nat Rev Immunol.* 2009; 9:429–39. [PubMed: 19461673]
124. Carson MJ, Dose JM, Melchior B, Schmid CD, Ploix CC. CNS immune privilege: hiding in plain sight. *Immunol Rev.* 2006; 213:48–65. [PubMed: 16972896]
125. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. *Nat Rev Neurosci.* 2007; 8:57–69. [PubMed: 17180163]
126. Kielian T. Microglia and chemokines in infectious diseases of the nervous system: views and reviews. *Front Biosci.* 2004; 9:732–750. [PubMed: 14766404]
127. Cartier L, Hartley O, Dubois-Dauphin M, Krause KH. Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases. *Brain Res Brain Res Rev.* 2005; 48:16–42. [PubMed: 15708626]
128. Maragakis NJ, Rothstein JD. Mechanisms of Disease: astrocytes in neurodegenerative disease. *Nat Clin Pract Neurol.* 2006; 2:679–689. [PubMed: 17117171]
129. Anderson CM, Swanson RA. Astrocyte glutamate transport: review of properties, regulation, and physiological functions. *Glia.* 2000; 32:1–14. [PubMed: 10975906]
130. Liberto CM, Albrecht PJ, Herx LM, Yong VW, Levison SW. Pro-regenerative properties of cytokine-activated astrocytes. *J Neurochem.* 2004; 89:1092–1100. [PubMed: 15147501]
131. Ridet JL, Malhotra SK, Privat A, Gage FH. Reactive astrocytes: cellular and molecular cues to biological function. *Trends Neurosci.* 1997; 20:570–577. [PubMed: 9416670]
132. Bushong EA, Martone ME, Jones YZ, Ellisman MH. Protoplasmic astrocytes in CA1 stratum radiatum occupy separate anatomical domains. *J Neurosci.* 2002; 22:183–192. [PubMed: 11756501]
133. Lau LT, Yu AC. Astrocytes produce and release interleukin-1, interleukin-6, tumor necrosis factor alpha and interferon-gamma following traumatic and metabolic injury. *J Neurotrauma.* 2001; 18:351–359. [PubMed: 11284554]
134. Kim SU, de Vellis J. Microglia in health and disease. *J Neurosci Res.* 2005; 81:302–313. [PubMed: 15954124]
135. Lieberman AP, Pitha PM, Shin HS, Shin ML. Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. *Proc Natl Acad Sci USA.* 1989; 86:6348–6352. [PubMed: 2474832]
136. Danton GH, Dietrich WD. Inflammatory Mechanisms after Ischemia and Stroke. *J Neuropathol Exp Neurol.* 2003; 62:127–136. [PubMed: 12578222]

137. Popovich PG, Longbrake EE. Can the immune system be harnessed to repair the CNS? *Nat Rev Neurosci.* 2008; 9:481–493. [PubMed: 18490917]
138. Frank-Cannon TC, Alto LT, McAlpine FE, Tansey MG. Does neuroinflammation fan the flame in neurodegenerative diseases. *Mol Neurodegener.* 2009; 4:47. [PubMed: 19917131]
139. Simard AR, Soulet D, Gowing G, Julien JP, Rivest S. Bone Marrow-Derived Microglia Play a Critical Role in Restricting Senile Plaque Formation in Alzheimer's Disease. *Neuron.* 2006; 49:489–502. [PubMed: 16476660]
140. Turrin NP, Rivest S. Tumor necrosis factor α but not interleukin 1β mediates neuroprotection in response to acute nitric oxide excitotoxicity. *J Neurosci.* 2006; 26:143–151. [PubMed: 16399681]
141. Penkowa M, Moos T, Carrasco J, Hadberg H, Molinero A, et al. Strongly compromised inflammatory response to brain injury in interleukin-6-deficient mice. *Glia.* 1999; 25:343–357. [PubMed: 10028917]
142. Prewitt CM, Niesman IR, Kane CJ, Houllé JD. Activated Macrophage/Microglial Cells Can Promote the Regeneration of Sensory Axons into the Injured Spinal Cord. *Exp Neurol.* 1997; 148:433–443. [PubMed: 9417823]
143. Group LMSS. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. University of British Columbia MS/MRI Analysis Group. *Neurology.* 1999; 53:457–465. [PubMed: 10449104]
144. Dheen ST, Kaur C, Ling EA. Microglial activation and its implications in the brain diseases. *Curr Med Chem.* 2007; 14:1189–1197. [PubMed: 17504139]
145. Price RW, Brew B, Sidtis J, Rosenblum M, Scheck AC, et al. The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. *Science.* 1988; 239:586–592. [PubMed: 3277272]
146. Spencer DC, Price RW. Human immunodeficiency virus and the central nervous system. *Annu Rev Microbiol.* 1992; 46:655–693. [PubMed: 1444270]
147. Watkins BA, Dorn HH, Kelly WB, Armstrong RC, Potts BJ, et al. Specific tropism of HIV-1 for microglial cells in primary human brain cultures. *Science.* 1990; 249:549–553. [PubMed: 2200125]
148. Dickson DW, Lee SC, Mattiace LA, Yen SH, Brosnan C. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. *Glia.* 1993; 7:75–83. [PubMed: 8423065]
149. Merrill JE, Chen IS. HIV-1, macrophages, glial cells, and cytokines in AIDS nervous system disease. *FASEB J.* 1991; 5:2391–2397. [PubMed: 2065887]
150. Benos DJ, Hahn BH, Bubien JK, Ghosh SK, Mashburn NA, et al. Envelope glycoprotein gp120 of human immunodeficiency virus type 1 alters ion transport in astrocytes: implications for AIDS dementia complex. *Proc Natl Acad Sci USA.* 1994; 91:494–498. [PubMed: 8290553]
151. Nuovo GJ, Alfieri ML. AIDS dementia is associated with massive, activated HIV-1 infection and concomitant expression of several cytokines. *Mol Med.* 1996; 2:358–366. [PubMed: 8784788]
152. Zhou L, Pupo GM, Gupta P, Liu B, Tran SL, et al. A parallel genome-wide mRNA and microRNA profiling of the frontal cortex of HIV patients with and without HIV-associated dementia shows the role of axon guidance and downstream pathways in HIV-mediated neurodegeneration. *BMC Genomics.* 2012; 13:677. [PubMed: 23190615]
153. Overall IP, Bell C, Mallory M, Langford D, Adame A, et al. Lithium Ameliorates HIV-gp120-Mediated Neurotoxicity. *Mol Cell Neurosci.* 2002; 21:493–501. [PubMed: 12498789]
154. Letendre SL, Woods SP, Ellis RJ, Atkinson JH, Masliah E, et al. Lithium improves HIV-associated neurocognitive impairment. *AIDS.* 2006; 20:1885–1888. [PubMed: 16954730]
155. White BC, Sullivan JM, DeGracia DJ, O'Neil BJ, Neumar RW, et al. Brain ischemia and reperfusion: molecular mechanisms of neuronal injury. *J Neurol Sci.* 2000; 179:1–33. [PubMed: 11054482]
156. Vila N, Castillo J, Dávalos A, Chamorro A. Proinflammatory Cytokines and Early Neurological Worsening in Ischemic Stroke. *Stroke.* 2000; 31:2325–2329. [PubMed: 11022058]
157. Ferrarese C, Mascarucci P, Zoia C, Cavarretta R, Frigo M, et al. Increased Cytokine Release From Peripheral Blood Cells After Acute Stroke. *J Cereb Blood Flow Metab.* 1999; 19:1004–1009. [PubMed: 10478652]

158. Tarkowski E, Rosengren L, Blomstrand C, Wikkelsö C, Jensen C, et al. Intrathecal release of pro- and anti-inflammatory cytokines during stroke. *Clin Exp Immunol.* 1997; 110:492–499. [PubMed: 9409656]
159. Kelly S, Zhao H, Hua Sun G, Cheng D, Qiao Y, et al. Glycogen synthase kinase 3 β inhibitor Chir025 reduces neuronal death resulting from oxygen-glucose deprivation, glutamate excitotoxicity, and cerebral ischemia. *Exp Neurol.* 2004; 188:378–386. [PubMed: 15246837]
160. Tsai LK, Wang Z, Munasinghe J, Leng Y, Leeds P, et al. Mesenchymal Stem Cells Primed With Valproate and Lithium Robustly Migrate to Infarcted Regions and Facilitate Recovery in a Stroke Model. *Stroke.* 2011; 42:2932–2939. [PubMed: 21836090]
161. Roh MS, Eom TY, Zmijewska AA, De Sarno P, Roth KA, et al. Hypoxia activates glycogen synthase kinase-3 in mouse brain in vivo: Protection by mood stabilizers and imipramine. *Biol Psychiatry.* 2005; 57:278–286. [PubMed: 15691529]
162. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, et al. Axonal Transection in the Lesions of Multiple Sclerosis. *N Engl J Med.* 1998; 338:278–285. [PubMed: 9445407]
163. Frohman EM, Racke MK, Raine CS. Multiple Sclerosis — The Plaque and Its Pathogenesis. *N Engl J Med.* 2006; 354:942–955. [PubMed: 16510748]
164. Merrill JE, Benveniste EN. Cytokines in inflammatory brain lesions: helpful and harmful. *Trends Neurosci.* 1996; 19:331–338. [PubMed: 8843602]
165. Simpson JE, Newcombe J, Cuzner ML, Woodroffe MN. Expression of monocyte chemoattractant protein-1 and other β -chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. *J Neuroimmunol.* 1988; 84:238–249. [PubMed: 9628469]
166. Hofman FM, Hinton DR, Johnson K, Merrill JE. Tumor necrosis factor identified in multiple sclerosis brain. *J Exp Med.* 1989; 170:607–612. [PubMed: 2754393]
167. Kang Z, Altuntas CZ, Gulen MF, Liu C, Giltiay N, et al. Astrocyte-Restricted Ablation of Interleukin-17-Induced Act1-Mediated Signaling Ameliorates Autoimmune Encephalomyelitis. *Immunity.* 2010; 32:414–425. [PubMed: 20303295]
168. Mycko MP, Papoian R, Boschert U, Raine CS, Selmaj KW. cDNA microarray analysis in multiple sclerosis lesions: detection of genes associated with disease activity. *Brain.* 2003; 126:1048–1057. [PubMed: 12690045]
169. De Sarno P, Axtell RC, Raman C, Roth KA, Alessi DR, et al. Lithium Prevents and Ameliorates Experimental Autoimmune Encephalomyelitis. *J Immunol.* 2008; 181:338–345. [PubMed: 18566399]
170. Booth DR, Arthur AT, Teutsch SM, Bye C, Rubio J, et al. Gene expression and genotyping studies implicate the interleukin 7 receptor in the pathogenesis of primary progressive multiple sclerosis. *J Mol Med (Berl).* 2005; 83:822–830. [PubMed: 16075257]
171. Beurel E, Yeh WI, Michalek SM, Harrington LE, Joep RS. Glycogen Synthase Kinase-3 Is an Early Determinant in the Differentiation of Pathogenic Th17 Cells. *J Immunol.* 2011; 186:1391–1398. [PubMed: 21191064]
172. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science.* 2005; 297:353–356. [PubMed: 12130773]
173. Araujo DM, Cotman CW. β -Amyloid stimulates glial cells in vitro to produce growth factors that accumulate in senile plaques in Alzheimer's disease. *Brain Res.* 1992; 569:141–145. [PubMed: 1611474]
174. Wisniewski HM, Vorbrodt AW, Wegiel J, Morys J, Lossinsky AS. Ultrastructure of the cells forming amyloid fibers in Alzheimer disease and scrapie. *Am J Med Genet.* 1990; (7):287–297.
175. Mrak RE, Sheng JG, Griffin WS. Glial cytokines in Alzheimer's disease: review and pathogenic implications. *Hum Pathol.* 1995; 26:816–823. [PubMed: 7635444]
176. Fillit H, Ding WH, Buee L, Kalman J, Altstiel L, et al. Elevated circulating tumor necrosis factor levels in Alzheimer's disease. *Neurosci Lett.* 1991; 129:318–320. [PubMed: 1745413]
177. Sly LM, Krzesicki RF, Brashler JR, Buhl AE, McKinley DD, et al. Endogenous brain cytokine mRNA and inflammatory responses to lipopolysaccharide are elevated in the Tg2576 transgenic mouse model of Alzheimer's disease. *Brain Res Bull.* 2001; 56:581–588. [PubMed: 11786245]
178. Bhat RV, Budd Haeberlein SL, Avila J. Glycogen synthase kinase 3: a drug target for CNS therapies. *J Neurochem.* 2004; 89:1313–1317. [PubMed: 15189333]

179. Sun X, Sato S, Murayama O, Murayama M, Park JM, et al. Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. *Neurosci Lett*. 2002; 321:61–64. [PubMed: 11872257]
180. Alvarez G, Muñoz-Montañó JR, Satrustegui J, Avila J, Bogóñez E, et al. Lithium protects cultured neurons against β -amyloid-induced neurodegeneration. *FEBS Lett*. 1999; 453:260–264. [PubMed: 10405156]
181. Wei H, Leeds PR, Qian Y, Wei W, Chen R, et al. β -Amyloid peptide-induced death of PC 12 cells and cerebellar granule cell neurons is inhibited by long-term lithium treatment. *Eur J Pharmacol*. 2000; 392:117–123. [PubMed: 10762662]
182. Nunes PV, Forlenza OV, Gattaz WF. Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. *Br J Psychiatry*. 2007; 190:359–360. [PubMed: 17401045]
183. Kessing LV, Søndergård L, Forman JL, Andersen PK. Lithium treatment and risk of dementia. *Arch Gen Psychiatry*. 2008; 65:1331–1335. [PubMed: 18981345]
184. Milligan ED, Watkins LR. Pathological and protective roles of glia in chronic pain. *Nat Rev Neurosci*. 2009; 10:23–36. [PubMed: 19096368]
185. Ren K, Dubner R. Interactions between the immune and nervous systems in pain. *Nat Med*. 2010; 16:1267–1276. [PubMed: 20948535]
186. Gao YJ, Ji RR. Chemokines, neuronal-glia interactions, and central processing of neuropathic pain. *Pharmacol Ther*. 2010; 126:56–68. [PubMed: 20117131]
187. Wieseler-Frank J, Maier SF, Watkins LR. Central proinflammatory cytokines and pain enhancement. *Neurosignals*. 2005; 14:166–174. [PubMed: 16215299]
188. Wieseler-Frank J, Maier SF, Watkins LR. Immune-to-brain communication dynamically modulates pain: physiological and pathological consequences. *Brain Behav Immun*. 2005; 19:104–111. [PubMed: 15664782]
189. Coyle DE. Partial peripheral nerve injury leads to activation of astroglia and microglia which parallels the development of allodynic behavior. *Glia*. 1998; 23:75–83. [PubMed: 9562186]
190. Honore P, Rogers SD, Schwei MJ, Salak-Johnson JL, Luger NM, et al. Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. *Neuroscience*. 2000; 98:585–598. [PubMed: 10869852]
191. Peters CM, Eisenach JC. Contribution of the Chemokine CCL2 to Mechanical Hypersensitivity Following Surgical Incision in Rats. *Anesthesiology*. 2010; 112:1250. [PubMed: 20395830]
192. Watkins LR, Hutchinson MR, Johnston IN, Maier SF. Glia: novel counter-regulators of opioid analgesia. *Trends Neurosci*. 2005; 28:661–669. [PubMed: 16246435]
193. DeLeo JA, Colburn RW, Nichols M, Malhotra A. Interleukin-6-mediated hyperalgesia/allodynia and increased spinal IL-6 expression in a rat mononeuropathy model. *J Interferon Cytokine Res*. 1996; 16:695–700. [PubMed: 8887053]
194. DeLeo JA, Colburn RW, Rickman AJ. Cytokine and growth factor immunohistochemical spinal profiles in two animal models of mononeuropathy. *Brain Research*. 1997; 759:50–57. [PubMed: 9219862]
195. Schäfers M, Svensson CI, Sommer C, Sorkin LS. Tumor necrosis factor- α induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. *J Neurosci*. 2003; 23:2517–2521. [PubMed: 12684435]
196. Ohtori S, Takahashi K, Moriya H, Myers RR. TNF- α and TNF- α receptor type 1 upregulation in glia and neurons after peripheral nerve injury: studies in murine DRG and spinal cord. *Spine*. 2004; 29:1082–1028. [PubMed: 15131433]
197. George A, Buehl A, Sommer C. Tumor necrosis factor receptor 1 and 2 proteins are differentially regulated during Wallerian degeneration of mouse sciatic nerve. *Exp Neurol*. 2005; 192:163–166. [PubMed: 15698630]
198. Reeve AJ, Patel S, Fox A, Walker K, Urban L. Intrathecally administered endotoxin or cytokines produce allodynia, hyperalgesia and changes in spinal cord neuronal responses to nociceptive stimuli in the rat. *Eur J Pain*. 2000; 4:247–257. [PubMed: 10985868]
199. Kwon BK, Fisher CG, Dvorak MF, Tetzlaff W. Strategies to promote neural repair and regeneration after spinal cord injury. *Spine*. 2005; 30:S3–S13.

200. Raghavendra V, Tanga F, DeLeo JA. Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. *J Pharmacol Exp Ther.* 2003; 306:624–630. [PubMed: 12734393]
201. Sweitzer SM, Schubert P, DeLeo JA. Propentofylline, a glial modulating agent, exhibits antiallodynic properties in a rat model of neuropathic pain. *J Pharmacol Exp Ther.* 2001; 297:1210–1217.
202. Ramos KM, Lewis MT, Morgan KN, Crysdale NY, Kroll JL, et al. Spinal upregulation of glutamate transporter GLT-1 by ceftriaxone: therapeutic efficacy in a range of experimental nervous system disorders. *Neuroscience.* 2010; 169:1888–1900. [PubMed: 20547213]
203. Nie H, Zhang H, Weng HR. Minocycline prevents impaired glial glutamate uptake in the spinal sensory synapses of neuropathic rats. *Neuroscience.* 2010; 170:901–912. [PubMed: 20678556]
204. Tawfik VL, Regan MR, Haenggeli C, Lacroix-Fralish ML, Nutile-McMenemy N, et al. Propentofylline-induced astrocyte modulation leads to alterations in glial glutamate promoter activation following spinal nerve transection. *Neurosci.* 2008; 152:1086–1092.
205. Sung B, Lim G, Mao J. Altered expression and uptake activity of spinal glutamate transporters after nerve injury contribute to the pathogenesis of neuropathic pain in rats. *J Neurosci.* 2003; 23:2899–2910. [PubMed: 12684477]
206. Nie H, Weng HR. Impaired glial glutamate uptake induces extrasynaptic glutamate spillover in the spinal sensory synapses of neuropathic rats. *J Neurophysiol.* 2010; 103:2570–2580. [PubMed: 20220084]
207. Weng HR, Aravindan N, Cata JP, Chen JH, Shaw AD, et al. Spinal glial glutamate transporters downregulate in rats with taxol-induced hyperalgesia. *Neurosci Lett.* 2005; 386:18–22. [PubMed: 15975716]
208. Doyle T, Chen Z, Muscoli C, Bryant L, Esposito E, Cuzzocrea S, et al. Targeting the Overproduction of Peroxynitrite for the Prevention and Reversal of Paclitaxel-Induced Neuropathic Pain. *J Neurosci.* 2012; 32:6149–6160. [PubMed: 22553021]
209. Mao J, Sung B, Ji RR, Lim G. Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity. *J Neurosci.* 2002; 22:8312–8323. [PubMed: 12223586]
210. Weng H, Chen J, Cata J. Inhibition of glutamate uptake in the spinal cord induces hyperalgesia and increased responses of spinal dorsal horn neurons to peripheral afferent stimulation. *Neuroscience.* 2006; 138:1351–1360. [PubMed: 16426766]
211. Weng HR, Chen JH, Pan ZZ, Nie H. Glial glutamate transporter 1 regulates the spatial and temporal coding of glutamatergic synaptic transmission in spinal lamina II neurons. *Neuroscience.* 2007; 149:898–907. [PubMed: 17935889]
212. Nie H, Weng HR. Glutamate transporters prevent excessive activation of NMDA receptors and extrasynaptic glutamate spillover in the spinal dorsal horn. *J Neurophysiol.* 2009; 101:2041–2051. [PubMed: 19211657]
213. Nie H, Zhang H, Weng HR. Bidirectional Neuron–Glia Interactions Triggered by Deficiency of Glutamate Uptake at Spinal Sensory Synapses. *J Neurophysiol.* 2010; 10:713–725. [PubMed: 20554846]
214. Jiang E, Yan X, Weng HR. Glial glutamate transporter and glutamine synthetase regulate GABAergic synaptic strength in the spinal dorsal horn. *J neurochem.* 2012; 12:526–536. [PubMed: 22339645]
215. Tawfik VL, Lacroix-Fralish ML, Bercury KK, Nutile-McMenemy N, Harris BT, et al. Induction of astrocyte differentiation by propentofylline increases glutamate transporter expression in vitro: heterogeneity of the quiescent phenotype. *Glia.* 2006; 54:193–203. [PubMed: 16819765]
216. Nie H, Zhang H, Weng HR. Minocycline prevents impaired glial glutamate uptake in the spinal sensory synapses of neuropathic rats. *Neuroscience.* 2010; 170:901–912. [PubMed: 20678556]
217. Parkitna JR, Obara I, Wawrzczak-Bargiela A, Makuch W, Przewlocka B, et al. Effects of Glycogen Synthase Kinase 3 β and Cyclin-Dependent Kinase 5 Inhibitors on Morphine-Induced Analgesia and Tolerance in Rats. *J Pharmacol Exp Ther.* 2006; 319:832–839. [PubMed: 16902054]

218. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. *Nat Methods*. 2012; 9:671–675. [PubMed: 22930834]

Figure 1.

GSK3 β and first neighbor interactions in *Homo sapiens*. The dark gray nodes represent interactions involved with proteins in non-signaling pathways. The light gray nodes represent interactions with proteins in signaling pathways. Schematic and interactions of GSK3 β were produced using PathwayLinker [37].

Figure 2.

The crystal structure of GSK3 β (Protein Data Bank PDBID: 1i09 [38]). A) The secondary structure of GSK3 β showing seven anti-parallel β strands at the N-terminal end and an α -helical domain at the C-terminal end. Cyan indicates a helix, magenta indicates a loop, and red indicates a sheet. B) The overall structure of GSK3 β . The N-terminal end is labeled green and encompasses residues 25-138, the C-terminal end is labeled blue and encompasses residues 139-343, and the activation loop is labeled yellow and encompasses residues 220-226 where Tyrosine-216 (red) is a phosphorylation site. C) A magnified view of Tyrosine-216, which is located in the activation loop. Figure was generated using PyMOL 1.4.1.

A **AR-A014418****B** **SB216763****Figure 3.**

The chemical structure of two GSK3 β inhibitors. A) The chemical structure of 1-(4-methoxybenzyl)-3-(5-nitrothiazol-2-yl) urea (AR-A014418) with the MW=308.31. B) The chemical structure of 3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (SB216763) with the MW=371.22 [39,99].

Figure 4.

Putative downstream pathways of GSK3 β that modulate the expression of pro-inflammatory and anti-inflammatory cytokines. Following GSK3 β activation, NF- κ B is translocated from the cytoplasm to the nucleus and binds transcriptional sites with CBP leading to an increase in the transcription of pro-inflammatory cytokines (IL-1 β , TNF- α , and IL-6). An increase in GSK3 β phosphorylation (inhibition of GSK3 β) results in an increase of CREB being translocated from the cytoplasm to the nucleus. This results in an increase in CBP binding with CREB at transcriptional sites, which increases the transcription of anti-inflammatory cytokine (IL-10). Green lines indicate an increase in activation and red lines indicate a decrease in activation.

Figure 5.

Chronic intraperitoneal injections (IP) of a GSK3 β inhibitor prevent the development of allodynia in a model of neuropathic pain. Rats were injected with the GSK3 β inhibitor, AR-014418 (0.3mg/kg), or vehicle(saline) 1 hr prior to surgery and then daily for 8 days following surgery. A von Frey filament with 1.5g force was used to stimulate the plantar region of the hind paw 10 times and the percentage of hindpaw withdrawal response to 10 time stimulations was used to indicate changes in nociceptive behaviors. Behavior tests were performed before surgery and then prior to the daily drug administration where the examiner was blinded to the types of treatment given to the rats. SHAM rats represent animals where the sciatic nerve was exposed but not ligated. Green represents the SHAM rats receiving vehicle treatment. Blue represents the pSNL group receiving vehicle treatment. Black represents the SHAM rats receiving the GSK3 β inhibitor treatment. Red represents the pSNL rats receiving the GSK3 β inhibitor. The percentage of hindpaw withdrawal response to the von Frey filament stimulation in pSNL rats receiving the GSK3 β inhibitor is significantly lower than that in pSNL rats receiving vehicle treatment, indicating that suppressing GSK3 β activities prevents the development of allodynia induced by nerve injury. The asterisks denote a significant difference between the AR-014418 treated pSNL group to the vehicle treated pSNL group. (n=5 per group, Unpaired students t-test. *P < 0.05 **P < 0.01).

Figure 6.

Partial sciatic nerve ligation results in a decrease in phosphorylated GSK3 β expression in the injured side of the dorsal horn 8 days following surgery. There was no significant difference in total expression of GSK3 β between the pSNL and sham operated rats. Eight days following surgery, rats were deeply anesthetized with pentobarbital (60 mg/kg, IP) and perfused intracardially with 200mL of heparinized 0.1 M PBS (pH=7.35) followed by 300mL of a solution containing 4% formaldehyde in 0.1 M PBS (pH=7.35). L4 and L5 spinal segment tissues were then fixed for 48 h at 4°C in the same fixative and cryoprotected for at least 24 h at 4°C in 30% sucrose in 0.1 M PBS (pH=7.35). Serial transverse sections, 30- μ m thick, were cut on a freezing microtome at -20°C and collected in 0.1M PBS and processed while free floating. The sections were then washed three times in 0.1 M PBS and then blocked with 10% normal goat serum plus 0.3% Triton X-100 in 0.1 M PBS (pH=7.35) for 1 h at room temperature. Sections were then incubated for 24 h at 4°C in rabbit anti-pGSK3 β (1:100) or anti-GSK3 β (1:200) in 4% normal goat serum plus 0.3% Triton X-100 in 0.1M PBS (pH=7.35). Sections were then washed 3 times and incubated with Texas Red goat anti-rabbit antibody (1:500) in 4% normal goat serum plus 0.3% Triton X-100 in 0.1M PBS (pH=7.35) for 2 h at room temperature. After rinsing in 0.1 M PBS, sections were mounted onto double frosted pre-cleaned microscope slides, air-dried, and cover slipped with UltraCruz Mounting Medium. Slides were imaged using an Olympus 1 $\times$ 71 Inverted Microscope with an Olympus DP72 Microscope Digital Camera. Images were processed using ImageJ (NIH) [218].

Figure 7.

Phosphorylated and total GSK3β are colocalized with neurons and astrocytes in the spinal dorsal horn. GFAP is a marker for astrocytes and NeuN is a marker for neuronal cells. Sections were incubated for 24 h at 4°C in rabbit anti-pGSK3β (1:100) or anti-GSK3β (1:200) in 4% normal goat serum plus 0.3% Triton X-100 in 0.1M PBS (pH=7.35). Sections were then washed 3 times and incubated with a combination of either mouse anti-NeuN Alexa Fluor 488 conjugated antibody (1:200) or mouse anti-GFAP Alexa Fluor 488 conjugated antibody (1:200) with Texas Red goat anti-rabbit antibody (1:500) in 4% normal goat serum plus 0.3% Triton X-100 in 0.1M PBS (pH=7.35) for 2 h at room temperature. After rinsing in 0.1 M PBS, sections were mounted, air-dried, cover slipped, and images mentioned in Figure 6.

Table 1

GSK3 β associated signaling pathways that are over expressed in *Homo sapiens*. Briefly, all first neighbor interactions of GSK3 β and all proteins of *Homo sapiens* are queried against different signaling pathways. Overrepresentation is determined if members of the different signaling pathways are increased in the first neighbor interactions of GSK3 β compared to all proteins. Signaling pathway indicates the signaling pathway along with the source. Displayed proteins indicate first neighbor interactions of GSK3 β . All proteins in pathway represent the total number of proteins implicated in the signaling pathway. Pathway Linker was used to identify overexpressed signaling pathways [37].

Signaling pathway	Displayed proteins	All proteins of pathway	P-value
Cancer (KEGG)	22	502	1.6×10^{-30}
WNT (KEGG)	16	229	1.2×10^{-25}
Prostate cancer (KEGG)	13	127	3.1×10^{-23}
Endometrial cancer (KEGG)	11	73	9×10^{-22}
INS (KEGG)	13	196	1×10^{-20}
Colorectal cancer (KEGG)	11	104	5.5×10^{-20}
SCLC (KEGG)	10	128	6.6×10^{-17}
NGF (Reactome)	11	211	1.6×10^{-16}
CML (KEGG)	9	112	1.9×10^{-15}
WNT (SignalLink)	9	149	2.6×10^{-14}
Pancreatic cancer (KEGG)	8	111	1.8×10^{-13}
Adhesion (KEGG)	10	312	5.3×10^{-13}
NSCLC (KEGG)	7	80	1.5×10^{-12}
AML (KEGG)	7	84	2.2×10^{-12}
Chemokine (KEGG)	9	243	2.2×10^{-12}
Glioma (KEGG)	7	97	6.1×10^{-12}
Apoptosis (KEGG)	7	134	6.1×10^{-11}
ErbB (KEGG)	7	145	1.1×10^{-10}
Melanogenesis (KEGG)	7	151	1.4×10^{-10}
Basal carcinoma (KEGG)	6	79	1.5×10^{-10}
MAPK (KEGG)	9	393	1.6×10^{-10}
Cell cycle (KEGG)	7	173	3.6×10^{-10}
Melanoma (KEGG)	6	95	4.7×10^{-10}
Tight junction (KEGG)	7	180	4.8×10^{-10}
B cell (KEGG)	6	118	1.8×10^{-9}
Opioid (Reactome)	5	79	1.4×10^{-8}
NT (KEGG)	6	187	2.8×10^{-8}
Adipocytokine (KEGG)	5	95	3.5×10^{-8}
VEGF (KEGG)	5	106	6.1×10^{-8}

Signaling pathway	Displayed proteins	All proteins of pathway	P-value
TGF-beta (SignalLink)	6	223	7.9×10^{-08}
Adherens junction (KEGG)	5	115	9.2×10^{-08}
Fc-gamma (KEGG)	5	124	1.3×10^{-07}
Wnt (Reactome)	4	56	2.6×10^{-07}
Bladder cancer (KEGG)	4	61	3.6×10^{-07}
Thyroid cancer (KEGG)	4	62	3.9×10^{-07}
Leukocyte (KEGG)	5	156	4.2×10^{-07}
Notch (Reactome)	3	16	4.5×10^{-07}
T cell (KEGG)	5	172	6.8×10^{-07}
MTOR (KEGG)	4	78	9.8×10^{-07}
Huntington (KEGG)	5	212	1.9×10^{-06}
P53 (KEGG)	4	93	2.0×10^{-06}
Fc-epsilon (KEGG)	4	101	2.8×10^{-06}
LTP (KEGG)	4	113	4.3×10^{-06}
Toll-like (KEGG)	4	145	1.2×10^{-05}
Smooth muscle (KEGG)	4	150	1.3×10^{-05}
Notch (KEGG)	3	62	2.9×10^{-05}
Notch (SignalLink)	3	64	3.2×10^{-05}
Immune (Reactome)	5	384	3.3×10^{-05}
EGF/MAPK (SignalLink)	5	388	3.5×10^{-05}
Axon (KEGG)	4	197	3.9×10^{-05}
JAK-STAT (KEGG)	4	203	4.3×10^{-05}
Ins receptor (Reactome)	3	76	5.4×10^{-05}
Alzheimer (KEGG)	4	227	6.7×10^{-05}
Hh (SignalLink)	3	85	7.5×10^{-05}
Cholerae infection (KEGG)	3	93	9.8×10^{-05}
IGF (SignalLink)	3	93	9.8×10^{-05}
Gap junction (KEGG)	3	115	1.8×10^{-04}
Oocyte (KEGG)	3	121	2.1×10^{-04}
GnRH (KEGG)	3	136	3.0×10^{-04}
Dorso-ventral (KEGG)	2	33	4.5×10^{-04}
Prion (KEGG)	2	45	8.4×10^{-04}
DNA-sensing (KEGG)	2	63	1.6×10^{-03}
E.coli infection (KEGG)	2	72	2.1×10^{-03}
Calcium (KEGG)	3	273	2.2×10^{-03}
Hedgehog (KEGG)	2	76	2.4×10^{-03}
Endocytosis (KEGG)	3	284	2.5×10^{-03}

Signaling pathway	Displayed proteins	All proteins of pathway	P-value
NOD-like (KEGG)	2	83	2.8×10^{-03}
RIG-I-like (KEGG)	2	87	3.1×10^{-03}
Actin (KEGG)	3	317	3.4×10^{-03}
Renal cancer (KEGG)	2	99	4.0×10^{-03}
Depression (KEGG)	2	102	4.2×10^{-03}
Helicobacter infection (KEGG)	2	103	4.3×10^{-03}
PtdIns (KEGG)	2	111	5.0×10^{-03}
TGF (KEGG)	2	112	5.1×10^{-03}
NK cell (KEGG)	2	189	0.014
TGF beta (Reactome)	1	15	0.014